Hong Kong Baptist University (HKBU) has recently entered into an agreement with Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (the Company) to establish a joint innovative research platform for Chinese medicines.  Through integrating their technologies and cooperation network, the two parties aim to conduct innovative research on Chinese medicines to build a modern, multi-disciplinary centre for innovative research in Chinese medicines with wide application prospects and international advanced standards, and serves as a think tank for the two parties in the R&D of new drugs and health products, such as health food products.

While the Company plans to provide research funding of HK$5 million, the School of Chinese Medicine, HKBU, will contribute technologies, and the two parties will join hands to conduct innovative research on Chinese medicines, submit joint applications for government research grants and send researchers to visit the partner for exchanges.  Planned collaborations include the study on proprietary Chinese medicines “Pien Tze Huang” treatment for chronic inflammatory conditions, development of health food products, and the study on other products of the Company in aspects of efficacy, composition, preparation and mechanism with a view to developing new drugs of higher technology.

Professor Albert Chan, President and Vice-Chancellor, HKBU, said that while the Company is a leading pharmaceutical enterprise in the country and its products are held in high regard both at home and overseas, SCM has considerable strength in new drug discovery based on Chinese medicines.   The collaboration will enhance the strengths of the two parties and benefit the Chinese medicines industry in the region as well as public health.